A Virginia-based technology firm led by an Indian American scientist is launching a new initiative to modernize the way academic medical centers conduct clinical research through artificial intelligence.
Jeeva Clinical Trials announced its Academic Medical Center (AMC) Partnership Program on Monday, offering institutions access to its “Agentic AI” platform.
The program is designed to replace fragmented, manual research methods with a unified digital infrastructure, targeting the “innovation gap” that often slows the transition of laboratory discoveries into life-saving treatments.
At the heart of this initiative is Dr. Harsha Rajasimha, the founder and CEO of Jeeva. Born and raised in Bengaluru, India, Rajasimha earned his undergraduate degree in computer science engineering from Bangalore University before moving to the United States in 2001.
His journey from the “Silicon Valley of India” to the forefront of U.S. biotechnology was fueled by personal tragedy, the loss of a child to a rare disease and a brother to type 1 diabetes.
READ: Indian American scholar maps the Milky Way’s hidden worlds (April 20, 2026)
“I felt uniquely positioned because of my Indian American scientist status,” Rajasimha said in a recent company profile, noting his experience navigating both healthcare systems.
After earning a master’s in computer science and a PhD in genetics and bioinformatics from Virginia Tech, he applied his training at the National Institutes of Health (NIH) and the FDA to solve the chronic “bottlenecks” of clinical trials.
The new partnership program provides academic researchers with AI tools that automate repetitive tasks, such as data cleaning and patient recruitment. By using what the company calls “Agentic AI,” the platform can reduce the manual burden on research staff by as much as 300%.
This is particularly critical for academic centers that lead the way in researching rare diseases but often lack the massive digital budgets of global pharmaceutical giants. Participants in the program will receive hands on training and workshops focused on decentralized trial design and regulatory compliance.
Read: Indian American researcher Meha Jain wins inaugural ASU-Science Prize (February 11, 2026)
The platform also supports investigator-initiated studies, allowing faculty and trainees to manage everything from protocol design to publication within a single, integrated software environment.
Beyond the technology, the program aims to humanize the process for participants. By enabling “bring your own device” mobile participation and remote monitoring, the AI driven platform reduces the travel burden on patients, a hurdle that often prevents diverse populations from joining critical studies.
As AI continues to reshape the life sciences landscape, Rajasimha’s crossborder perspective remains a driving force. By bridging his Indian educational roots with American computational expertise, he is working to ensure that the next generation of physicians is equipped to bring treatments to patients faster than ever before.